Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

232.65 2.70 −1.15%
Market cap
$34.8B
P/E
41.0×
Fwd P/E
31.5×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
4.58% 7.70% 7.39% 9.31%

+8 more TTM periods

Piotroski F-Score
3 4 4 5
ROA
2.76% 4.77% 4.50% 5.59%
ROIC
3.11% 5.69% 5.61% 6.71%
Return on Tangible Assets
13.08% 14.90% 14.89% 18.44%
Average Days of Receivables
68.63 50.29 49.54 49.83
Free Cash Flow per Share
17.20 16.31 13.78 15.43
Free Cash Flow
2,540.00 2,401.30 2,019.20 2,262.10
Capital Expenditures
(338.80) (189.50) (185.40) (191.50)
Other line items
Cash ROIC
9.26% 8.22% 7.12% 7.95%
Accounts Receivable Turnover
5.71 5.91 7.20 6.92
Accounts Payable Turnover
6.42 6.50 5.62 5.96
Inventory Turnover
1.12 1.15 1.04 1.07
Average Days of Payables
56.53 53.72 65.59 60.50
Days of Inventory on Hand
333.72 292.04 329.16 323.58
Tax Rate
(0.17) (0.15) (0.17) (0.16)
Research and Development Expense of Revenue
20.08% 18.95% 17.98% 17.71%
Selling, General and Administrative Expense of Revenue
25.87% 24.84% 24.61% 24.15%
Share Based Compensation of Revenue
2.95% 2.96% 2.94% 3.04%
Operating CF/Net income
3.45 1.89 1.71 1.53
Depreciation/Fixed assets
0.45 0.38 0.35 0.31
Capex/Depreciation
(0.25) (0.16) (0.17) (0.20)
Revenue per Share
67.89 67.51 67.51 68.66
Operating CF per Share
19.49 17.60 15.05 16.74
Capex per Share
(2.29) (1.29) (1.27) (1.31)
Capex to Sales
0.03 0.02 0.02 0.02

Fold the line items

Columns are period end dates